Edgewise Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2019 | — | $-16.9M | $23.7M |
| Mar 2020 | — | $-20.0M | $20.9M |
| Jun 2020 | — | $-23.8M | $16.9M |
| Sep 2020 | — | $-27.3M | $38.7M |
| Dec 2020 | — | $-33.4M | $104.9M |
| Mar 2021 | — | $306.4M | $221.0M |
| Jun 2021 | — | $296.8M | $50.4M |
| Sep 2021 | — | $285.4M | $10.6M |
| Dec 2021 | — | $274.4M | $15.6M |
| Mar 2022 | — | $260.4M | $34.5M |
| Jun 2022 | — | $246.4M | $18.3M |
| Sep 2022 | $59.0K | $361.4M | $109.7M |
| Dec 2022 | — | $346.7M | $22.0M |
| Mar 2023 | — | $328.8M | $48.2M |
| Jun 2023 | — | $311.5M | $31.8M |
| Sep 2023 | — | $290.4M | $33.0M |
| Dec 2023 | — | $318.8M | $86.1M |
| Mar 2024 | — | $534.9M | $30.3M |
| Jun 2024 | — | $510.5M | $43.5M |
| Sep 2024 | — | $488.9M | $44.8M |
| Dec 2024 | — | $459.2M | $41.7M |
| Mar 2025 | — | $429.7M | $49.9M |
| Jun 2025 | — | $589.1M | $43.4M |
| Sep 2025 | — | $558.6M | $46.0M |
| Dec 2025 | — | $522.3M | $61.1M |
| Mar 2026 | — | $493.2M | $33.2M |
| Jun 2026 | — | $448.1M | $72.3M |